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had been exposed to nitrofurantoin during the first trimester of 
pregnancy. Exposure to nitrofurantoin was not associated with an 
increased risk of birth defects in general (adjusted OR, 0.850 [95% 
CI, 0.669–1.080]) or specific malformations.
Conclusion: First-trimester exposure to nitrofurantoin was not asso-
ciated with increased risk for major birth defects as well as other 
specific malformations.
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Introduction: Understanding the gap between evidence-based medi-
cine and clinical practice is necessary to improve clinical outcomes in 
children. This study aimed to investigate the most used drugs, ana-
lyzed in defined daily doses (DDD), in the Danish paediatric wards 
within 1 year.
Patients (or Materials) and Methods: Data were extracted from a 
Danish database, which contains information about the number of 
DDD sold to the hospital pharmacies including what is sold to the 
pediatric wards, hereby estimating the pediatric drug use. Two analy-
ses were made regarding the drug consumption. A main analysis cov-
ering the 90% most used drugs where the extent of off-label use and 
the number of drugs having a Pediatric Investigation Plan (PIP) were 
explored. Nationwide, 16 hospitals were included representing both 
general and specialized pediatric departments. Secondly, a test sample 
analysis was made regarding drug use during hospital admission, 
covering 80% of the pediatric standard medicine assortments from 
3 hospitals; results from the remaining hospitals are being prepared.
Results: One hundred drugs constituted the 90% most used drugs 
in the pediatric wards. Divided by anatomical classification (ATC), 
treatment of infections (J), drugs used for alimentary tract and metab-
olism problems (A), and antineoplastic and immunomodulating 
agents (L) were most prescribed. The subgroup L has not been among 
the most used ATC groups before, the expenses for this subgroup 
constitutes 25% of the entire pediatric medicine budget. Fifteen drugs 
(15%) were by all indications off label, the amount of DDD used off 
label accounted for 9.2%. A PIP existed on 25 drugs in total. The 
average time from central authorization to completed PIP was 8.5 
years, and 32% of the PIPs were completed by 2013. Preterm and 
newborns were included in 25% of the PIPs and adolescents in 64%. 
In the test sample 71% of the drugs were repeated when compared 
with the results from the main analysis. The immunomodulating 
agents were not included. Contrary to the main analysis, drugs aimed 
at the nervous system (N) were among the most used subgroups.
Conclusion: The PIP is a fairly new step toward evidence-based 
medicine ensuring the safety, efficacy, and positive risk-benefit bal-
ance by assessing clinical trials in children. However, only one fourth 
of 100 most used drugs in pediatric wards have a PIP and only 8 of 
these are completed. As a consequence, off-label drug use is frequent 
in Danish children and rational guidance regarding prescriptions in 
several areas is needed.
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Introduction: Daptomycin is a lipopeptide antibiotic with rapid con-
centration-dependent bactericidal action against Gram-positive organ-
isms. Target daptomycin plasma concentrations have been determined 
in animal models for some pathogens, but data on optimal exposure in 
humans are still lacking. Measurement of daptomycin plasma concentra-
tion is available at our institution since 2009 and is performed regularly. 
The aim was to assess variability of daptomycin plasma concentrations 
and the main determinants influencing daptomycin exposure.
Patients (or Materials) and Methods: We retrospectively collected 
data in patients with at least 1 determination of daptomycin plasma 
concentrations during the period of January 2009 to February 2012 
at the University Hospital of Zurich. Samples were analyzed by 
LC-MS/MS. Because daptomycin is mainly eliminated by the kid-
neys, exposure in patients with no renal replacement therapy (nRT), 
intermittent RT (iRT), and continuous RT (cRT) was compared. A 
trough level (Cmin) of at least 10 mg/L and a minimal peak level (Cmax) 
of 50 mg/L were defined as optimal based on animal data.
Results: Ninety patients were identified with a mean (SD) age of 
59 (16) years and a mean body weight of 74 (21) kg with 15 (16%) 
patients having a BMI > 30. The mean total daptomycin dose was 448 
(133) mg (range, 175–1000 mg). In 22%, daptomycin was adminis-
tered every 48 hours and in 1% every 36 hours. Mean Cmax was 66.2 
mg/L (n = 247; range, 20–236 mg/L) and mean Cmin was 16.7 mg/L 
(n = 116; range, 2–68 mg/L). Cmax and Cmin levels were significantly 
lower in cRT (52 [20] mg/L and 9.5 [7] mg/L, respectively) compared 
with nRT (75.6 [42] mg/L and 21.4 [16] mg/L, P < 0.0001). Cmin 
below 10 mg/L was found in 69% of cRT, in 35% of iRT, and 26% 
of nRT and Cmax was below 50 mg/L in 52% of cRT, 8% of iRT, and 
27% of nRT. When controlling for plasma creatinine and albumin 
concentration, dose interval, administered dose/kg and BMI, cRT 
remained significantly associated with an increased risk of a Cmin level 
below 10 mg/L (OR = 3.1; P= 0.001) compared with nRT. There was 
an inverse and independent association between administered dose/
kg and Cmax below 50 mg/L (OR = 2.0; P = 0.003). Trough levels 
> 20 mg/L were mainly seen in nRT patients with renal impairment 
with only 2 cases of mild CK elevation.
Conclusion: Daptomycin exposure is highly variable depending on 
renal function and renal replacement therapy used. Patients undergo-
ing cRT had the highest proportion of low daptomycin exposure with 
the highest risk for possible under dosing.
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Introduction: Guidelines caution prescribers and patients against 
chronic benzodiazepine use (BZD). Nevertheless, BZD use among 
nursing home residents remains high. We focused on individual resi-
dents and explored benefit and harm of chronic BZD use, willingness 
to try, and barriers against the discontinuation of chronic BZD use by 
questioning the general practitioner (GP) and the nurse.
Patients (or Materials) and Methods: In this cross-sectional study, 
we selected nursing home residents with at least 3 months of BZD 
use. A resident-specific questionnaire was addressed to the GP and 
nurse. For every resident, the GP and nurse had to score 8 barrier 
statements on a 10 point Likert scale. Additionally, we collected 10 
general attitudes scored by GPs and nurses. The questionnaire was 
based on an expert meeting and was pretested.
Results: We received data for 109 chronic BZD users. GPs and nurses 
indicated that the BZD still had the desired effect in, respectively, 
87% and 83% of the residents, and that except for dependence; 
there were no observed side effects in 75% and 70% of the residents. 
Overall, GPs had higher barriers than the nurses. Nevertheless, the 
willingness to stop among GPs was higher (respectively 33% vs. 
21%). Both caregivers were willing to stop in 13% of the residents. 
The most common barriers against discontinuation was for both 
caregivers the fear that initial problems will come back and the pref-
erence of a pharmacologic treatment instead of a nonpharmacologic 
treatment. The GPs perceived the resident’s motivation as a larger 
barrier than the nurses (median, 9 vs 7; P = 0.001) and indicated 
more often that discontinuation of BZDs can lead to an increase in 
care burden (median, 8 vs 6; P = 0.028). Of all 10 general statements, 
the most common attitude among both GPs and nurses was that the 
longer the resident takes the medication, the more difficult it is to stop 
(median, 8), and the resident’s old age makes it difficult and unneces-
sary to stop. Nurses, in contrast to the GPs, indicated that there is 
little knowledge on alternative strategies to handle troubles when 
stopping BZDs (median, 7 vs 2; P < 0.001) and little scientific infor-
mation available for stopping (median, 6 vs 2; P = 0.004). The scores 
for resident-specific barriers were higher than for general statements.
Conclusion: The perceived effectiveness, the absence of side effects 
and the presence of dependence in most residents that use BZD 
chronically, result in a low willingness to stop. Implementation of 
discontinuation initiatives have to address different barriers of differ-
ent parties requiring multidisciplinary evaluation of residents.
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Introduction: The ICH E7 guideline for studies involving geriatric 
patients intends to improve the knowledge about medicines in that 
population. As a legislative document, it might not reflect the needs 
of health care professionals. This study investigated what information 
health care professionals, regulatory agencies, and pharmaceutical 
industries actually consider necessary for rational drug prescribing 
to older individuals.
Patients (or Materials) and Methods: A 29-item questionnaire was 
composed, focusing on the representation of older individuals in tri-
als, the pharmacokinetics, efficacy and safety, and the convenience of 
use of medicinal products. Forty-three European physicians, pharma-
cists, ethicists, regulators, and professionals from the pharmaceuti-
cal industry, all specialized in medication for older individuals were 
included. A second questionnaire was composed of 11 control items 
and 5 new items, based on comments. Median scores, differences 
between clinical and nonclinical respondents, and the consistency of 
responses were analyzed.
Results: Thirty-seven (86%) respondents returned the initial ques-
tionnaire: 23 clinicians and 14 nonclinical professionals. The second 
was returned by 21 clinicians and 10 nonclinical professionals (31/37 
[84%]). There were no significant differences between respondents 
regarding 10 control items. Information about 32 (94%) of the 34 
items was considered necessary. Information about age-related dif-
ferences in adverse events, locomotor effects, drug–disease interac-
tions, dosing instructions, and information about the proportion of 
included 65+ patients was considered necessary by most respondents. 
The clinicians considered information significantly more important 
than did the nonclinical respondents about the inclusion of 75+, time 
until benefit in older people, anticholinergic effects, drug–disease 
interactions, and the convenience of use.
Conclusion: This study reveals that items considered necessary are 
currently not included in the ICH E7 guideline or its supplement, 
the Q&A document; namely, information about effects on the loco-
motor system, drug–disease interactions, and dosing instructions. 
Also, clinicians’ and nonclinicians’ opinions differed significantly in 
15% of the items. Therefore, all stakeholders should collaborate to 
improve the availability of information for the rational prescribing 
of medicines to older individuals.
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Introduction: Health care professionals in daily practice use national 
handbooks for rational prescribing of medicines to older patients. 
The study objective was to investigate the availability and clinical 
applicability of such information in European and American hand-
books.
Patients (or Materials) and Methods: The Belgian Repertorium, 
German Rote Liste, British National Formulary (BNF), Dutch 
Farmacotherapeutisch Kompas (FK), and American Physician’s Desk 
Reference (Concise Monograph and Product Label [PL]) were ana-
lyzed. All 35 nongeneric medicines for diseases frequently present 
in older people with a first European centralized approval between 
2008 and 2011 and an FDA approval before October 2012 were 
included. A 19-item checklist, based on the ICH-E7 criteria, was used 
